SEC Form 4 · accession 0001144204-17-031283
Cytosorbents Corp · CTSO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Phillip P. Chan
Officer — President and CEO · Director
Period of report
Jun 5, 2017
Accepted (ET)
Jun 6, 2017 · 4:10 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001175151
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 5, 2017 | P | 6,300 | $4.00 | A | 396,207 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Includes (i) the following restricted stock units ("RSUs") that will be settled into common stock upon vesting upon a "Change In Control" of CytoSorbents Corporation, as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan: (a) 18,700 RSUs granted on February 24, 2017, (b) 57,000 RSUs granted on June 7, 2016, and (c) 130,000 RSUs granted on April 8, 2015, (ii) the following RSUs subject to vesting as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting: (a) 40,625 RSUs granted on February 24, 2017 and (b) 26,000 RSUs granted on June 7, 2016 and (iii) 123,882 shares of common stock owned by the reporting person (including 6,300 shares of common stock purchased in the open market on June 5, 2017 and reported on this Form 4).